| Not Yet Recruiting | Chronic Kidney Disease and Metabolic Disorders in the Elderly NCT07494526 | Chinese PLA General Hospital | — |
| Recruiting | Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients NCT07116746 | Arthrosi Therapeutics | Phase 2 |
| Not Yet Recruiting | Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients NCT07168551 | Assiut University | — |
| Recruiting | This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialys NCT07144332 | Sohag University | — |
| Recruiting | Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model NCT06981663 | Örebro University, Sweden | — |
| Recruiting | Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision NCT07400549 | China National Center for Cardiovascular Diseases | N/A |
| Enrolling By Invitation | Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia NCT07001865 | Ningbo No. 1 Hospital | — |
| Active Not Recruiting | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) NCT06846515 | Arthrosi Therapeutics | Phase 3 |
| Recruiting | A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuric NCT06859073 | Novo Nordisk A/S | Phase 1 |
| Recruiting | A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease NCT06310967 | Intelligem Therapeutics Australia Pty Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospi NCT06586229 | Assiut University | — |
| Recruiting | CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive S NCT06463561 | Hospital Universitario La Paz | Phase 4 |
| Completed | A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects NCT06501534 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Active Not Recruiting | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) NCT06439602 | Arthrosi Therapeutics | Phase 3 |
| Completed | The Effect of Exercise at Different Time Intervals on Hyperuricemia NCT06315569 | Xijing Hospital | N/A |
| Completed | Effect of Increased Daily Water Intake in Patients With Hyperuricemia NCT06315543 | Xijing Hospital | N/A |
| Active Not Recruiting | PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function NCT06729853 | Shanton Pharma Pte. Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuri NCT06603142 | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | Phase 2 / Phase 3 |
| Completed | Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects NCT06168929 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Effectiveness of Digital Health Intervention on Community Health Care in Middle-aged and Older Population in T NCT07238257 | Chang Gung Memorial Hospital | N/A |
| Recruiting | Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia NCT06629376 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Completed | Effect of Tigulixostat on the Pharmacokinetics of Theophylline NCT06189404 | LG Chem | Phase 1 |
| Unknown | The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia NCT06084585 | Amway (China) R&D Center | N/A |
| Completed | Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia NCT06056570 | Urica Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia NCT06591767 | Liaquat University of Medical & Health Sciences | N/A |
| Completed | Relationship Between Intestinal Flora Changes and Hyperuricemia Under Chronic Psychological Stress NCT06984575 | Shanghai 10th People's Hospital | — |
| Completed | Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency an NCT05954169 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia NCT05913310 | Quan Jiang | Phase 4 |
| Completed | SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects NCT06678581 | Shanton Pharma Co., Ltd. | Phase 1 |
| Completed | Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients NCT05586971 | LG Chem | Phase 3 |
| Completed | Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients NCT05586958 | LG Chem | Phase 3 |
| Completed | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients NCT05504083 | InventisBio Co., Ltd | Phase 2 |
| Active Not Recruiting | Imagery as Biomarker of Gout NCT05434858 | Lille Catholic University | N/A |
| Terminated | Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney NCT04987294 | Allena Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuric NCT05574036 | Tanta University | Phase 2 |
| Completed | Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Topha NCT05253833 | Arthrosi Therapeutics | Phase 2 |
| Recruiting | Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases NCT05476627 | Peking Union Medical College Hospital | — |
| Unknown | Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals NCT05245890 | Ningbo No. 1 Hospital | — |
| Completed | Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets NCT05168683 | Allena Pharmaceuticals | Phase 1 |
| Unknown | Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation NCT06119802 | Yinglong Hou | — |
| Completed | Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients NCT05474560 | Ain Shams University | Phase 4 |
| Active Not Recruiting | Treat-to-target by Email During Urate-lowering Therapy in Gout NCT04733079 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for NCT05226013 | The Affiliated Hospital of Qingdao University | Phase 1 |
| Completed | Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients NCT05119686 | Arthrosi Therapeutics | Phase 2 |
| Completed | Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Femal NCT04966325 | LG Chem | EARLY_Phase 1 |
| Completed | Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clini NCT06652035 | Liaquat University of Medical & Health Sciences | — |
| Completed | Clinical Effect Observation of Barley Green Intervention in Hyperuricemia Population and Related Mechanism Stu NCT06876909 | Peking University People's Hospital | N/A |
| Completed | Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults NCT04886050 | LG Chem | Phase 1 |
| Completed | An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) NCT04987242 | Allena Pharmaceuticals | Phase 2 |
| Unknown | Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Invol NCT04953533 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia NCT06718062 | Hansung University | Phase 4 |
| Completed | Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) NCT04829435 | Allena Pharmaceuticals | Phase 1 |
| Unknown | Hyperuricemia and Diabetic Nephropathy NCT04799925 | Assiut University | — |
| Completed | Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C) NCT04938024 | University of Minnesota | N/A |
| Completed | Vegan Diet, Amla Fruits and Uric Acid NCT04801745 | Fu Jen Catholic University | N/A |
| Withdrawn | Post-Authorisation Safety Study of Lesinurad NCT04072471 | AstraZeneca | — |
| Completed | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia NCT04638543 | Atom Therapeutics Co., Ltd | Phase 2 |
| Completed | A Safety and Tolerability Study of FCN-207 in Healthy Volunteers NCT04622124 | Fochon Pharmaceuticals, Ltd. | Phase 1 |
| Unknown | Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteer NCT04586803 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers NCT04236219 | Allena Pharmaceuticals | Phase 1 |
| Unknown | Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women NCT04463940 | Barzilai Medical Center | — |
| Unknown | Role of Uralyt-U in Patients With Hyperuricemia NCT04352153 | Ai Peng | N/A |
| Completed | Mass Balance Study of [14C]LC350189 in Healthy Volunteers NCT04070846 | LG Chem | Phase 1 |
| Unknown | Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction NCT03534037 | National Defense Medical Center, Taiwan | Phase 4 |
| Completed | The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults NCT04139824 | LG Chem | Phase 1 |
| Unknown | Uric Acid Lowering Trial in Youth Onset T2D NCT03899883 | University of Colorado, Denver | Phase 2 |
| Unknown | A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia NCT04180982 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia NCT03934099 | LG Chem | Phase 2 |
| Completed | Renal PK Study of LC350189 NCT04066712 | LG Chem | Phase 1 |
| Completed | Effect of the Consumption of a Combination of Plant Extracts (BSL_EP026) on Serum Uric Acid. NCT04165499 | Biosearch S.A. | EARLY_Phase 1 |
| Completed | The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. NCT03927677 | LG Chem | Phase 1 |
| Unknown | The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia NCT04157959 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 NCT04060173 | Atom Therapeutics Co., Ltd | Phase 1 |
| Unknown | Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no S NCT04012294 | Instituto Nacional de Cardiologia Ignacio Chavez | Phase 3 |
| Unknown | The Effects of Rhus Coriaria L. on Serum Uric Acid Levels NCT02891031 | Shiraz University of Medical Sciences | N/A |
| Terminated | Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease NCT03865407 | Virginia Commonwealth University | Phase 2 |
| Unknown | Effect of Oxalate and Urate Metabolism on CKD Evolution NCT04399915 | The Institute of Nephrology of the Academy of Medical Sciences of Ukraine | — |
| Completed | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynami NCT04040816 | Shanton Pharma Co., Ltd. | Phase 2 |
| Unknown | The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA） NCT03691688 | Shanghai Zhongshan Hospital | — |
| Unknown | Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Tri NCT04199325 | The Affiliated Hospital of Inner Mongolia Medical University | N/A |
| Completed | Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid NCT03648996 | University of Missouri-Columbia | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjec NCT03906006 | Atom Therapeutics Co., Ltd | Phase 1 |
| Completed | Nutraceutical on Hyperuricemia NCT04161872 | University of Pavia | Phase 4 |
| Completed | The Diet Gout Trial NCT03569020 | Johns Hopkins University | N/A |
| Unknown | The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome NCT03473951 | National Defense Medical Center, Taiwan | — |
| Unknown | Prevalence of Hyperuricemia in Pakistan NCT03473444 | OBS Pakistan | — |
| Terminated | Hyperuricemia and Left Ventricular Diastolic Function NCT03495999 | National Defense Medical Center, Taiwan | — |
| Completed | Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia NCT03185793 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients NCT03200210 | Sun Yat-sen University | Phase 4 |
| Completed | Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level NCT03211403 | Atridia Pty Ltd. | Phase 1 |
| Completed | Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria NCT03118739 | AstraZeneca | Phase 2 |
| Withdrawn | Gender Differences in the Metabolic Effects of Uric Acid NCT03076684 | University of Missouri-Columbia | EARLY_Phase 1 |
| Completed | Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients NCT03149939 | Benha University | N/A |
| Unknown | The Intervention of Multi-vitamin With Minerals to Hyperuricemia NCT03218709 | Sun Yat-sen University | Phase 4 |
| Unknown | Effect of Hyperuricaemia on Chronic Renal Disease NCT03425708 | The Affiliated Hospital of Xuzhou Medical University | Phase 4 |
| Completed | The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics NCT02956278 | University of California, San Francisco | Phase 4 |
| Completed | Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood NCT02959918 | Selecta Biosciences, Inc. | Phase 2 |
| Unknown | Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients NCT02944214 | Shanghai 10th People's Hospital | N/A |
| Completed | Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types) NCT02837198 | Fuji Yakuhin Co., Ltd. | Phase 2 |
| Completed | Study of URC102 to Assess the Safety and Efficacy in Gout Patients NCT02557126 | JW Pharmaceutical | Phase 2 |
| Terminated | Pharmacogenetics of SGLT2 Inhibitors NCT02462421 | University of Maryland, Baltimore | Phase 4 |
| Completed | Study of FYU-981 in Hyperuricemia With or Without Gout NCT02416167 | Fuji Yakuhin Co., Ltd. | Phase 2 |
| Completed | Compare the Renal Protective Effects of Febuxostat and Benzbromarone NCT02338323 | Shanghai 10th People's Hospital | N/A |
| Completed | The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients NCT02338128 | Shanghai 10th People's Hospital | — |
| Completed | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients W NCT02252835 | Gilead Sciences | Phase 2 |
| Completed | Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients NCT02290210 | JW Pharmaceutical | Phase 2 |
| Completed | Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia NCT02213562 | Hiroshima University | N/A |
| Completed | Study of FYU-981 in Hyperuricemia With or Without Gout NCT02344862 | Fuji Yakuhin Co., Ltd. | Phase 2 |
| Unknown | Long-term Prednisone Use for End-stage Heart Failure NCT02282683 | Hebei Medical University | Phase 2 / Phase 3 |
| Unknown | Effect of Allopurinol Treatment on Insulin Resistance NCT02008968 | Istanbul Medeniyet University | N/A |
| Unknown | Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy NCT01984749 | Freed Study Group | N/A |
| Completed | Zurig (Febuxostat) 40mg Efficacy and Safety Trial NCT02600780 | Getz Pharma | Phase 4 |
| Unknown | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syn NCT01818505 | National Taiwan University Hospital | — |
| Completed | Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial NCT01881919 | University of Leeds | EARLY_Phase 1 |
| Completed | Purine Metabolism Enzyme SNP to Uric Acid Production NCT01830725 | Keesler Air Force Base Medical Center | — |
| Completed | Impact of Blueberries on Uric Acid and Quality of Life NCT01532622 | University of Mississippi Medical Center | N/A |
| Unknown | Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout NCT01519687 | Pharmos | Phase 2 |
| Unknown | Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia NCT02502565 | Washington D.C. Veterans Affairs Medical Center | — |
| Completed | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to NCT01407874 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Pati NCT01416402 | Gilead Sciences | Phase 2 |
| Completed | Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals NCT01363869 | Chiang Mai University | N/A |
| Completed | Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 NCT01361646 | LG Life Sciences | Phase 1 |
| Completed | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout NCT01336686 | Gilead Sciences | Phase 2 |
| Completed | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol NCT01265264 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes NCT03636529 | University of Memphis | N/A |
| Completed | Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO) NCT01109121 | Nuon Therapeutics, Inc. | Phase 2 |
| Completed | Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia NCT00921375 | Virchow Group | Phase 3 |
| Completed | Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia NCT01052987 | Nuon Therapeutics, Inc. | Phase 2 |
| Unknown | Safety and Efficacy Study of Intramuscular Uricase-PEG 20 NCT01038947 | EnzymeRx | Phase 1 |
| Unknown | Safety and Efficacy Study of Intravenous Uricase-PEG 20 NCT01021241 | EnzymeRx | Phase 1 |
| Completed | Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia NCT00995618 | Nuon Therapeutics, Inc. | Phase 2 |
| Completed | Gout Dose Response Study NCT00955981 | Ardea Biosciences, Inc. | Phase 2 |
| Completed | The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome NCT00868673 | Instituto Nacional de Cardiologia Ignacio Chavez | N/A |
| Completed | Prednisone for Heart Failure Patients With Hyperuricemia NCT00919243 | Hebei Medical University | Phase 4 |
| Completed | Lowering Serum Uric Acid to Prevent Acute Kidney Injury NCT00756964 | University of Florida | Phase 2 |
| Completed | Primary Prevention of Hypertension in Obese Adolescents NCT00288158 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout NCT00741442 | Ardea Biosciences, Inc. | Phase 2 |
| Completed | The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure NCT00978653 | Istanbul University | N/A |
| Terminated | Rasburicase (Fasturtec) Registration Trial NCT00607152 | Sanofi | Phase 3 |
| Completed | Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status NCT01931527 | Washington University School of Medicine | N/A |
| Completed | Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia. NCT04144088 | Chung Shan Medical University | Phase 2 |
| Completed | Rasburicase in Tumor Lysis Syndrome NCT00302653 | Sanofi | Phase 4 |
| Completed | Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients NCT00186940 | St. Jude Children's Research Hospital | — |
| Completed | Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome NCT00230178 | Sanofi | Phase 3 |
| Completed | Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patie NCT00230217 | Sanofi | Phase 4 |
| Completed | Treatment of Hyperuricemia in Patients With Heart Failure NCT00422318 | Tottori University Hospital | Phase 4 |
| Completed | Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma NCT00631579 | Sanofi | Phase 2 |
| Completed | Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome NCT00563771 | Sanofi | Phase 4 |
| Terminated | Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodg NCT00664144 | Sanofi | Phase 2 |
| Completed | Magnetic Resonance Imaging in Subjects With Gouty Tophi NCT00174954 | Takeda | — |
| Completed | Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor o NCT03921736 | Anna Posadzy-Małaczyńska | Phase 4 |
| Completed | Allopurinol in Chronic Heart Failure NCT00997542 | National Heart and Lung Institute | Phase 4 |
| Completed | Phase II Exploratory Clinical Study of KUX-1151 NCT02190786 | Kissei Pharmaceutical Co., Ltd. | Phase 2 |